--- title: "Palatin Tech | 10-Q: FY2026 Q3 Revenue: USD 3.921 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286317465.md" datetime: "2026-05-13T21:02:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286317465.md) - [en](https://longbridge.com/en/news/286317465.md) - [zh-HK](https://longbridge.com/zh-HK/news/286317465.md) --- # Palatin Tech | 10-Q: FY2026 Q3 Revenue: USD 3.921 M Revenue: As of FY2026 Q3, the actual value is USD 3.921 M. EPS: As of FY2026 Q3, the actual value is USD -0.37. EBIT: As of FY2026 Q3, the actual value is USD -1.729 M. ### Segment: Life Science #### Revenue Total collaboration and license revenue for Palatin Technologies, Inc. was $3,920,675 for the three months ended March 31, 2026, compared to $0 for the same period in 2025. For the nine months ended March 31, 2026, total collaboration and license revenue was $12,884,261, compared to $0 for the same period in 2025. Revenue for the three months ended March 31, 2026, included $3,751,122 from the Altanispac Agreement. For the nine months ended March 31, 2026, revenue included $3,751,122 from the Altanispac Agreement and $9,133,139 from the BI Agreement. #### Net Loss Palatin Technologies, Inc. reported a net loss of -$1,432,987 for the three months ended March 31, 2026, compared to -$4,811,420 for the same period in 2025. The net loss for the nine months ended March 31, 2026, was -$4,019,314, a significant reduction from the -$15,077,551 reported for the nine months ended March 31, 2025. The accumulated deficit as of March 31, 2026, was -$463,093,213. #### Operating Expenses - **Research and Development (R&D) Expenses** - Overall R&D expenses decreased to $3,517,223 for the three months ended March 31, 2026, from $3,755,158 in the prior year period. For the nine months ended March 31, 2026, overall R&D expenses were $10,362,756, down from $12,928,391 in the prior year period, primarily due to reduced spending on MCR programs. - Spending on MCR programs increased to $2,012,143 for the three months ended March 31, 2026, from $1,853,851 in the prior year period. However, for the nine months ended March 31, 2026, MCR program spending decreased to $5,272,845 from $7,822,953 in the prior year period. - General R&D spending was $1,505,080 and $5,089,911 for the three and nine months ended March 31, 2026, respectively, down from $1,901,307 and $5,105,438 for the corresponding periods in 2025, mainly due to a decrease in compensation-related expenses. - Cumulative R&D spending from inception to March 31, 2026, totaled approximately $311,900,000 for the Vyleesi program and $257,900,000 for all other programs. - **General and Administrative (G&A) Expenses** - G&A expenses increased to $1,984,446 for the three months ended March 31, 2026, from $1,474,019 in the prior year period. For the nine months ended March 31, 2026, G&A expenses rose to $6,769,994 from $5,176,794 in the prior year period, attributed to higher compensation costs and professional fees. #### Other Income (Expense) Total other income (expense), net, was $148,007 for the three months ended March 31, 2026, and $229,175 for the nine months ended March 31, 2026. This represents an increase compared to $1,757 and $111,634 for the respective periods in 2025, driven by higher investment income partially offset by lower interest expense and foreign currency translation losses. #### Cash Flow - **Operating Cash Flow** - Net cash used in operating activities was -$10,843,290 for the nine months ended March 31, 2026, a decrease from -$17,217,595 for the nine months ended March 31, 2025, primarily due to recognized collaboration and license revenue. - **Investing Cash Flow** - Net cash used in investing activities was -$51,299 for the nine months ended March 31, 2026, mainly for the purchase of property and equipment. For the nine months ended March 31, 2025, net cash provided by investing activities was $2,500,000 from the sale of Vyleesi. - **Financing Cash Flow** - Net cash provided by financing activities was $18,489,818 for the nine months ended March 31, 2026, including $16,910,891 from equity financing and $1,598,441 from warrant exercises, offset by -$19,514 for withholding taxes. For the nine months ended March 31, 2025, net cash provided was $7,710,261, including $3,398,237 from warrant exercises and $4,457,520 from common stock sales, offset by -$99,482 for withholding taxes and -$46,014 for finance lease obligations. #### Liquidity and Capital Resources As of March 31, 2026, Palatin Technologies, Inc. had cash and cash equivalents of $10,159,494, other receivables of $2,167,215, and current liabilities of $2,536,002. #### Future Outlook and Strategy Management expects existing cash and cash equivalents to fund operations through the next twelve months following the issuance of the financial statements, based on current operating and development plans and the ability to reduce or delay operating expenses. The company will require additional funding for clinical trials and regulatory applications. Palatin Technologies, Inc. focuses its strategy on advancing a differentiated portfolio of melanocortin receptor-targeted therapeutics, emphasizing MC4R agonists for rare neuroendocrine obesity disorders, leveraging strategic partnerships, and implementing a disciplined capital strategy. The company is also actively discussing with potential partners and licensees to progress non-obesity products. ### Related Stocks - [PTN.US](https://longbridge.com/en/quote/PTN.US.md) ## Related News & Research - [Palatin to Begin Trading on Nasdaq Stock Exchange | PTN Stock News](https://longbridge.com/en/news/286812696.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Financial year ending 31 March 2026 reports final results.](https://longbridge.com/en/news/287166907.md) - [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)